

AUTOIMMUNE PANCREATITIS (AIP): Pancreatic and Extrapancreatic Findings on CT and MR

N Takahashi, MD • KD Bodily JG Fletcher, MD • JL Fidler, MD • DM Hough, MD • A Kawashima, MD • ST Chari, MD MAYO CLINIC, DEPARTMENTS OF RADIOLOGY AND GASTROENTEROLOGY, ROCHESTER, MN

NTRODUCTION

Autoimmune nancreatitis (AIP) is an autoimmune systemic disease that predominantly involves the pancreas in a unique form of chronic pancreatitis. The most commonly involved organs outside the pancreas are the biliary ductal system causing intra- and extra-hepatic biliary strictures, the retroperitoneum causing retroperitoneal fibrosis, the salivary glands and the kidneys. Involvement of the lungs, liver, lymph nodes, gastrointestinal tract, thyroid, and prostate have also been previously

CLINICAL FEATURES OF AIP

Mostly male

50 years of age or older

Clinical Manifestations: jaundice (74%), weight loss (47%), and abdominal pain (45%)

 Elevation of serum IgG4 is a good diagnostic marker of AIP with a reported sensitivity and specificity of 95% and 97%, respectively, for the differentiation of the AIP from pancreatic cancer.

Steroid therapy is effective in relieving symptoms and preserving the pancreatic function as well as other organs effected by AIP.

DIAGNOSTIC CRITERIA OF AIP

The Japan Pancreas Society suggested criteria for AIP. Alternative diagnostic criteria incorporating two additional criteria of other organ involvement and response to the steroid therapy of pancreatic enlargement/biliary strictures have been advocated.

DIAGNOSTIC CRITERIA FOR AUTOIMMUNE PANCREATITIS*

Group I. (Original Features Proposed by the Japanese Pancreas Society) Diffuse gland enlargement by CT or MR

2. Diffuse narrowing of the main pancreatic duct (at least 1/3rd of total length) by ERCP 8. Elevated serum IgG4 or characteristic histologic changes e pancreatitis is established when all 3 criteria are fulfille

roup II. (Diagnostic Criteria Proposed by Mayo Clinic Investigators) . Histologic features of Lymphoplasmocytic Sclerosing Pancreatitis

Diagnosis of autoimmune nancreatitis is established when histological criteria are fulfilled Group III. (Diagnostic Criteria Proposed by Mayo Clinic Investigators 1. Typical or atypical pancreatic findings by CT or MR

Elevation of serum IgG4 or other organ involvement Response to steroid therapy iaonosis of autoimmune pancreatitis is established when all 3 criteria are fulfilled

uosis of autoimmune pancreatitis using any of the above criteria gr lignant diseases such as pancreatic or biliary cancers.

MAGING

Radiological evaluation is essential in making the diagnosis of AIP. Differentiating AIP from pancreatic cancer is the main role of radiologists to avoid unnecessary surgery or invasive intervention. However, the unique clinical presentation of AIP can be difficult to differentiate from pancreatic cancer. AIP represents 2-6% of patients who undergo pancreatic resection for suspected pancreatic cancer and represents 31% of nefactive chronic pancreatitis who undergo pancreatic resection Radiologists should be aware of various pancreatic manifestations of AIP including diffuse enlargement, focal enlargement, and frank mass formation. Extrapancreatic involvement is relatively common in patients with AIP, which may occur synchronously with the pancreatic manifestation or may occur later. One should be aware of imaging appearances of the extrapancreatic involvement. Presence of such apancreatic involvement in association with atypical pancreatic findings should raise the possibility of AIP.

FYPICAL PANCREATIC FINDINGS • Featureless border (Fig. 1, 2) Diffuse parenchymal enlargement (Fig. 1, 2) This is due to swelling and inflammation

Decreased enhancement during the pancreatic phase with increasing enhancement during the hepatic phase (Fig. 2). MR appearance: slightly increased T2 signal relative to normal pancreatic that distorts the normal architecture of the pancreatic parenchyma. DIFFERENTIAL DIAGNOSIS parenchyma (Fig 1C).

 Capsule-like rim (Fig. 3) • Diffuse pancreatic lymphoma (Fig. 4) Soft tissue surrounding pancreas that is seen in • Diffuse pancreatic carcinoma one-third of patients with AIP. This finding is • Acute pancreatitis (differentiate clinically) ion on CT, and low signal intensity on both T1and T2-weighted MR.

FIGURE 1

FIGURE 2

of the pancreas gland (A). Pancreatic duct irreg eal fibrosis in this case.

 Diffuse or focal narrowing of the pancreatic duct. This is best appreciated on ERCP and may be difficult to see on CT/MR. On CT/MR, secondary irregular focal duct dilatation may be seen (Fig. 1)

• Focal, mass-like enlargement (Fig. 5-7) · Involvement of adjacent vascular structures Normal or atrophic parenchyma (Fig. 9) Pseudocyst formation (Fig. 10)

Calcification

PANCREATIC FINDINGS



can be challenging, particular

DIFFERENTIAL DIAGNOSIS

• Pancreatic malignancy (Fig. 8)

· Other forms of pancreatitis

obstruction (Fig. 7b)

Differentiating AIP from malignanc

FIGURE 9





FIGURE 11





BILIARY FINDINGS DIFFERENTIAL DIAGNOSIS Biliary involvement is seen in about 80% of patients with AIP and is the Primary schlerosing cholangitis most common form of extrapancreatic involvement. It mostly involves the cholangitis ower common bile duct causing Cholangiocarcinoma oiliary stricture. Multifocal intra hepatic or upper extrahepatic bile duct strictures resembling primary ERCP findings: The biliary strictures in AIP tend to be longer (3 mm or sclerosing cholangitis (PSC) can be longer) compared to the band-like present in 10-35% of patients. Ra strictures (2 mm or less) typical of soft tissue mass develops which ca PSC. Beaded appearance or resemble cholangiocarcinoma. Findings include: diverticulum-like outpouching of the absent in patients with AIP. These Bile duct enhancement and features are difficult to characterize on MRCP. thickening (Fig. 13) Associated areas of biliary

bile duct, typical findings of PSC, are








FIGURE 15







EXTRAPANCREATIC FINDINGS

Renal involvement is seen in imately 35% of patients with AIP, with renal parenchyma involved in 30% and renal sinus or renal pelvis wall involved in 10-15%. Renal parenchymal lesions are often bilateral and multiple, and predominantly involve the renal cortex. Findings include: · Parenchymal involvement: 1. well-defined or ill-defined round lesions (Fig. 17) 2. well-defined wedge-shaped lesions (Fig. 18) 3. small (<1cm) peripheral cortical

· Perinephric involvement 1. circumferential perinephric rim 2. renal sinus nodule 3. renal pelvis wall thickening CT appearance: low attenuation in the pancreatic phase with gradually increasing enhancement in the portal phase MR appearance: isotensity on T1WI and low intensity on T2WI, low intensity on T1WI after gadolinium administration

DIFFERENTIAL DIAGNOSIS Pyelonephritis Lymphoma nodules (Fig. 19) 4. diffuse involvement (Fig. 20) Vascular insult

FIGURE 19





FIGURE 18



OTHER EXTRAPANCREATIC FINDINGS





alivary Glands

(Sjogren-like syn



ST, Smyrk TC, Levy MJ, Topasian MD, Iohi N, Zhang L, Clain JE, Pearson RX, en BT, Wege SS, Farnell MB. Diagnosis of remane panceatitis: the Mayo Clinic	5.	Kamisawa T, Egewa N, Nakajima H, Tsuruta K, Okamoto A. Extrapancreatic lesions in autoimmune pancreatitis. J Clin Gastroenterol, 2005. 39(10): p. 904-907.	10	Society M.o.t.c.f.a.p.o.t.I.P. Diagnostic crite for autoimmune pancreatitis by the Jap Pancreas Society J Jpn Pan Soc, 2002. 17: 585-587.
ence. Olin Gastroenterol Hepatol. 2006 (8):1010-6; quiz 934. no H, Kawa S, Horiuchi A, Utro H, Foruya N, utsu T, Fukushima M, Nikaido T, Nakayama utsu N, Kivolawa K. Haiti serum IbG4	6.	Kamisawa T, Funata N, Hayashi X, Eshi X, Kolke M, Tsunsta K, Okamoto A, Egawa N, Nakajima H. A new clinicopathological entity of IgG4-esiated autoimmune disease. J Gastroenterol, 2003. 38(10): n. 982-4.		 Jakahashi N, Kawashima A, Pietcher JG, Chair Ronal Involvement in Patients with Autoimm Pancreattis: CT and MR Findings: Radiology Pess. Welsbergshi T, Kawaura Y, Satomus Y, Watani
ntsations in patients with sciencing antis. N Eng J Med, 2001. 344(10): p. 1 H A, Kawa S, Hamano H, Hayama M, Ota H, wa K. EROP features in 27 patients with	7.	Kawamoto S, Siegelman SS, Hsuban RH, Fishman EK. Lymphoplasmacytic sclerosing panceatitis with obstructive jauncice: CT and pathology features. AR Am J Reentgenol, 2004. 183(4): p. 915-21.		H, Motoo Y, Okui T, Sawabu N. Clinical and imag features of autoimmune pancesattis with fo pancesatic swelling or maks formali comparison with so-called tamor-form pancesattis and pancesatic carcinoma. An
mune pancreatitis. Gastrointest Endosc, 55(4): p. 494-9.	8.	Okazaki K, and Chiba T. Autoimmune related pancreatitis. Gut, 2002. 51(1): p. 1-4.	13	Gastroenterol, 2003. 98(12): p. 2679-87. . Yoshida K, Toki F, Takeuchi T, Watanabe S, Shira
Honda H, Baba S, Kuroisea T, Voshimibu K, T, Jimi M, Samii T, Masuda K, Antoimmune nattis: CT and MR characteristics. AIR Am J genel, 1998: 170(5): p. 1323-7.	9.	Sahani DI, Kalva SP, Fareel J, Maher MM, Saini S, Musller PP, Lausens GY, Fernandez CD, Wanhaw AL, Simeona JF. Actoinmune pancruatitic imaging features. Radiology. 2004. 233(2): p. 345-52.		K. Hajsohi N. Orronic panceatitis caused by autoimmune abnormality. Proposal of the conc of autoimmune panceatitis. Dig Dis Sci, 199 40(7): p. 1561-8.



FIGURE 12 FIGURE 13



post-treatment pancreas can be normal

sized or atrophic



FIGURE 10

dilatation (Fig. 13 • Soft tissue mass (Fig. 16)

Diffuse gallbladder wall thickening

FIGURE 13

